Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ever Fortune.AI Co's Debt-to-EBITDA or its related term are showing as below:
ROCO:6841'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.15 Med: -0.05 Max: 3.64
Current: 3.64
During the past 8 years, the highest Debt-to-EBITDA Ratio of Ever Fortune.AI Co was 3.64. The lowest was -0.15. And the median was -0.05.
ROCO:6841's Debt-to-EBITDA is ranked worse than 68.67% of 482
companies
in the Healthcare Providers & Services industry
Industry Median: 2.185
vs ROCO:6841: 3.64
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ever Fortune.AI Co Debt-to-EBITDA Related Terms
Ever Fortune.AI Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ever Fortune.AI Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6841 vs VEEV, BTSG, HQY: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, Ever Fortune.AI Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ever Fortune.AI Co Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ever Fortune.AI Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ever Fortune.AI Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Ever Fortune.AI Co (ROCO:6841) has a Debt-to-EBITDA of 9.05 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ever Fortune.AI Co. According to the industry distribution chart, Ever Fortune.AI Co ranks #331 out of 482 companies in the Healthcare Providers & Services industry, placing it in the top 68.7%.
Is Ever Fortune.AI Co's Debt-to-EBITDA too high?
Ever Fortune.AI Co's current Debt-to-EBITDA is 9.05. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Ever Fortune.AI Co's value of 9.05 is 314.2% above this industry median. Based on the distribution chart, Ever Fortune.AI Co ranks #331 out of 482 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Ever Fortune.AI Co has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ever Fortune.AI Co's Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Ever Fortune.AI Co ranks #331 out of 482 companies for Debt-to-EBITDA. This places Ever Fortune.AI Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. Ever Fortune.AI Co's value of 9.05 is 314.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ever Fortune.AI Co's current Debt-to-EBITDA of 9.05 is 314.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ever Fortune.AI Co. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ever Fortune.AI Co's current Debt-to-EBITDA is 9.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ever Fortune.AI Co stock overvalued right now?
Based on GuruFocus' analysis, Ever Fortune.AI Co (ROCO:6841) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.45, compared to a current price of NT$54.30 — trading 49.5% below its estimated fair value. The current Debt-to-EBITDA is 9.05 and 314.2% above the Healthcare Providers & Services industry median of 2.19. Ever Fortune.AI Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ever Fortune.AI Co (ROCO:6841), the current Debt-to-EBITDA is 9.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ever Fortune.AI Co (ROCO:6841) Overvalued in 2026?
Based on GuruFocus' analysis, Ever Fortune.AI Co stock appears to be undervalued.
The current stock price of NT$54.30 is trading 49.5% below its estimated GF Value™ of NT$107.45.
GuruFocus considers Ever Fortune.AI Co to be Significantly Undervalued.
Key valuation signals for ROCO:6841:
Debt-to-EBITDA: 9.05
GF Value™: NT$107.45 vs. price of NT$54.30 (49.5% below fair value)
Industry Position: 314.2% above the Healthcare Providers & Services median (#331 of 482)
No single metric tells the full story. See the ROCO:6841 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ever Fortune.AI Co Ltd is composed of establishing a cloud medical platform based on medical Big data, and to provide customized medical artificial intelligence solutions and services in various biomedical fields. The results both provide a professional second opinion for doctors and assist clinical doctors in making a medical diagnosis, which in turn raises the speed, accuracy, and efficiency of medical decisions. The products of the company include: Medical Artificial Intelligence, Cloud Biomedical Platform, and Medical Big Data. Its segments are: Medical AI Department; Biotechnology Department; and Others, where maximum revenue is derived from Biotechnology Department segment. Geographically, it operates in Taiwan, U.S.A., and Vietnam, of which maximum revenue is generated from Taiwan.
77GF Score
Get the complete analysis for ROCO:6841
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6841 has been successfully added to your 
